On Nov. 2, 2020, Innovation Pharma announced receipt of written feedback from the FDA that is in general agreement with the Companyﾒs planned clinical trial for Brilacidin, a defensin-mimetic drug candidate, for treatment of COVID-19.

Target enrollment for the trial was 120 patients. Contract Research Organizations were secured to expedite trial enrollment with many clinical sites expressing interest in participating in the study. The Company anticipated commencement of the Brilacidin for COVID-19 clinical trial in 4Q 2020.